[ad_1]
MEETING OF PLYMOUTH, Pa., March 21, 2019 / PRNewswire / – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, is safe, tolerable, and generates strong T-cell and antibody responses. These phase 1 data have been published in The infectious diseases journal and further supports the advancement of the intradermal delivery platform for emerging infectious diseases. Significantly, the study demonstrated that intradermal administration (skin) with CELLECTRA from Inovio® 100% of the evaluable subjects generated antigen-specific antibody responses that persisted for more than one year in most subjects and generated T cell responses that were equivalent to or better than those in the administered group. intramuscular route. The published data further confirm the benefits of Inovio's immunization and immunotherapy platform in terms of safety, potency and stability of the product.
Dr. J. Joseph Kim, President of Inovio, "INO-4201 has already demonstrated protection in 100% of non-human primates following a challenge related to a lethal dose of Ebola.By strong preclinical and human data, Inovio is in train to exert its overall development strategy of promoting the INO-4201 as a viable reserve vaccine, since it can be used many times without anti-vector protection, so it could be used to strengthen the &-420 420 420 & & & & & & & & & Efficacy of the Vaccine Vaccine We are now seeking funding from our partners to advance our Ebola vaccine as a stand-alone vaccine, as well as to stimulate people previously immunized with viral vector vaccines. "
Unlike viral vector vaccines that must remain frozen, INO-4201 is stable at room temperature for more than one year. Simple, room-stable, non-living vaccine approaches are desirable to control outbreaks of Ebola virus.
The Inovio Ebola vaccine was evaluated in five groups of healthy subjects. Of 70 subjects evaluated, 67 (96%) had seroconversion and a strong antibody response to the Ebola glycoprotein antigen after the three-dose immunization regimen; 52 subjects (76%) seroconverted after only two doses.
Significantly, in the arm of the study using intradermal (skin) administration, 13 of the 13 evaluable subjects (100%) generated antigen-specific antibody responses after only two doses and all remained seropositive after three immunizations.
To date, INO-4201 has been well tolerated and has not demonstrated serious systemic adverse effects, such as fever, joint pain and low white blood cell counts, reported in badociation with certain Ebola vaccines. based on viral vectors currently under development.
More information on this study, fully funded by DARPA, is available in the latest issue of The infectious diseases journal in the article titled "Intradermal SynCon® The Ebola GP DNA vaccine is temperature stable and safely demonstrates the benefits of cellular and humoral immunogenicity in healthy volunteers, "written by Inovio and colleagues.
About Inovio Pharmaceuticals, Inc.
Inovio is an advanced biotechnology company developing and commercializing immunotherapies and DNA-based vaccines that transform the treatment and prevention of cancer and infectious diseases. The proprietary technology platform of Inovio applies antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. Technology works exclusively in vivoand has been shown to consistently activate robust and fully functional T-cell and antibody responses against targeted cancers and pathogens. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical pre-cancer. Phase 2 immuno-oncology programs targeting HPV-related cancers, bladder cancer and glioblastoma, as well as platform development programs for hepatitis B, Zika virus, Ebola, MERS and HIV are also under development. Partners and collaborators include AstraZeneca, Regeneron, Roche / Genentech, ApolloBio Corporation, Wistar Institute, Bill & Melinda Gates Foundation, University of Pennsylvania, Parker Institute for Cancer Immunotherapy, CEPI, DARPA, Life Sciences GeneOne, Life Sciences Plumbline, NIH, HIV Vaccine Test Network, National Cancer Institute, Walter Reed Army Research Institute , Drexel University, and Laval University. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation- and DNA-based drug and gene delivery technologies, our expectations for our research and development programs, including the planned launch and completion of clinical trials and the availability and timing of data from these trials. Actual events or results may differ from the expectations set forth herein due to a number of factors, including uncertainties inherent in preclinical studies, clinical trials and product development programs, availability of funds to support research continuous and studies undertaken. to prove the safety and effectiveness of electroporation technology as a mechanism of administration or to develop viable DNA vaccines, our ability to support our portfolio of products from the market. SynCon® active immunotherapy and vaccines, the ability of our employees to reach the developmental and commercial stages of our products under sales license allowing us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more effective or less costly than previous ones. any therapy or treatment that we and our collaborators hope to develop, product liability issues, patents, and whether they or their licenses will provide us with significant protection against third parties using the technologies covered, that such proprietary rights are opposable or defensible or infringe upon the rights of others or allegedly infringed. can support disability actions and if we can fund or devote other important resources that may be required to sue, protect or defend them, the level of business expenses, the valuation of our technology by potential partners or collaborators or collaborators, financial market conditions, the impact of government proposals on health care and other factors set out in our annual report on Form 10-K for the year ended the December 31, 2018 and other regulatory filings that we make from time to time. There can be no badurance that the product candidates in our product portfolio will be developed, manufactured or marketed successfully, that the final results of the clinical trials will support the regulatory approvals required to market licensed products, or that the forward-looking information provided herein. document will be proved accurate. Forward-looking statements speak only as of the date of this press release and we badume no obligation to update or revise such statements, except as required by law.
View original content for multimedia download: http: //www.prnewswire.com/news-releases/inovios-ebola-vaccine-deleded-intradermally-demonstrates-100-immunogenicity-in-a-clinical-study-published-in- the -journal-of-infectious-diseases-300816369.html
SOURCE Inovio Pharmaceuticals, Inc.
[ad_2]
Source link
